By successfully replacing the defective RPE65 gene with a functional copy, Luxturna not only provided a groundbreaking treatment for patients with RPE65-associated retinal dystrophy but also initiated substantial investment and research into gene therapies for a broader spectrum of IRDs. The gene discussed is RPE65; the disease is inherited retinal dystrophy.